GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » ROE % Adjusted to Book Value

Implantica AG (OSTO:IMP A SDB) ROE % Adjusted to Book Value : 0.00% (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG ROE % Adjusted to Book Value?

Implantica AG's ROE % for the quarter that ended in . 20 was 0.00%. Implantica AG's PB Ratio for the quarter that ended in . 20 was N/A. Implantica AG's ROE % Adjusted to Book Value for the quarter that ended in . 20 was N/A.

Implantica AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Implantica AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG ROE % Adjusted to Book Value Chart

Implantica AG Annual Data
Trend
ROE % Adjusted to Book Value

Implantica AG Semi-Annual Data
ROE % Adjusted to Book Value

Competitive Comparison of Implantica AG's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Implantica AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Implantica AG's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Implantica AG's ROE % Adjusted to Book Value falls into.


;
;

Implantica AG ROE % Adjusted to Book Value Calculation

Implantica AG's ROE % Adjusted to Book Value for the fiscal year that ended in . 20 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Implantica AG's ROE % Adjusted to Book Value for the quarter that ended in . 20 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Implantica AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Implantica AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Implantica AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
Traded in Other Exchanges
8IM1:Germany
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Website
https://www.implantica.com
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines